Pulsed Laser Light and Nano-encapsulated Ocular Dyes for Advanced Therapies in the Eye

DYE-LIGHT aims to enhance ocular drug delivery and safety by utilizing low-energy pulsed-lasers with nano-encapsulated dyes to facilitate targeted treatment of severe ocular diseases.

Subsidie
€ 1.499.351
2023

Projectdetails

Introduction

Ocular diseases affect the quality of life of millions of patients. Despite improvements in pharmacological treatments, the arsenal of medications to treat severe ocular diseases today remains rather restricted to traditional drugs.

Need for Novel Administration Methods

The use of most modern biotherapeutics like proteins and nucleic acids could be a major step forward. However, current ways of administration such as eye drops and intravitreal injections are no longer sufficient to deliver these drugs to most targets in the eye. Therefore, novel concepts allowing biotherapeutics to safely overcome ocular barriers are of high interest.

Safety Concerns in Ocular Surgery

In ocular surgery, pulsed-lasers (P-Ls) are used for ‘tissue cutting’, though safety concerns remain. DYE-LIGHT hypothesizes that strategies which would allow the use of P-Ls in the eye at much lower energy than today could considerably improve safety and pave the way for both novel ocular therapies and advanced surgical interventions.

Exploration of Vital Dyes

DYE-LIGHT will explore vital dyes, as used by ocular surgeons to stain tissues, as photosensitizers. DYE-LIGHT follows the recent observation that P-L irradiation of ocular dyes can result in the formation of water vapor nanobubbles (‘dye-based nanobubbles’) and thermophoretic transport (‘dye-based thermophoresis’).

Energy Efficiency

Interestingly, these biophysical phenomena occur at a laser energy that is ~ 1000 times less than a P-L alone. As compared to free dyes, dyes encapsulated in nanocarriers are expected to penetrate less into the retina, which might improve safety.

Focus on Nano-Encapsulated Dyes

Therefore, the focus in DYE-LIGHT will be on nano-encapsulated ocular dyes. DYE-LIGHT will explore the potential of dye-based nanobubbles for:

  1. Delivery of nucleic acids in the corneal endothelium
  2. Spatial selective vitreolysis in the eye

Controlled Transport of Nanomedicines

Finally, DYE-LIGHT will explore dye-based thermophoresis for controlled transport of nanomedicines injected in the vitreous towards the retina. If successful, this might open new perspectives to improve the efficacy of retinal drug and gene delivery.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.499.351
Totale projectbegroting€ 1.499.351

Tijdlijn

Startdatum1-9-2023
Einddatum31-8-2028
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • UNIVERSITEIT GENTpenvoerder

Land(en)

Belgium

Vergelijkbare projecten binnen European Research Council

ERC Proof of...

Method for Integrated All-Optical Biological Analysis at Scale

Developing an all-optical platform for precise optogenetic probing and automated data analysis to enhance research in neuroscience, developmental biology, and cancer.

€ 150.000
ERC Starting...

Targeting epilepsy with phototherapeutics

This project aims to develop targeted photoactivatable drugs to control focal epilepsy, minimizing side effects and potentially transforming treatment options for intractable cases.

€ 1.499.375
ERC Starting...

Engineering of bacteria to see light

EOS aims to develop biohybrid living materials by inducing light sensitivity in motile bacteria for remote drug delivery, using a novel "optobacterial-stimulation" method.

€ 1.500.000
ERC Proof of...

Optical imaging platform for high-throughput longitudinal studies of the eye in disease models

The OPTIMEYEZ project aims to enhance a novel multi-contrast optical imaging platform for non-invasive retinal studies, facilitating drug development in neurological diseases while reducing animal use.

€ 150.000
ERC Starting...

Lensless label-free nanoscopy

This project aims to develop deep UV lensless holotomographic nanoscopy for high-resolution, large-field imaging of live cells to enhance understanding of extracellular vesicles as disease biomarkers.

€ 1.500.000

Vergelijkbare projecten uit andere regelingen

EIC Pathfinder

LUMINESCENT IMPLANTS AS PORTS FOR LIGHT-BASED THERAPIES

The project aims to develop PhotoTheraPorts for localized light delivery to enhance anti-inflammatory and neuroinhibitory drug efficacy, improving treatment precision for neuropathic pain and epilepsy.

€ 2.999.840
EIC Accelerator

Direct Selective Laser Trabeculoplasty (DSLT): Accessible glaucoma care in seconds

BELKIN Vision's Direct Selective Laser Trabeculoplasty (DSLT) aims to revolutionize glaucoma treatment with an automated, non-contact device that simplifies the procedure for widespread use.

€ 2.500.000
EIC Pathfinder

Next Generation Glioma Treatments using Direct Light Therapy

GlioLighT aims to revolutionize glioma treatment by developing Direct Light Therapy (DLT) for targeted ROS generation, enhancing efficacy and safety while eliminating the need for toxic photosensitisers.

€ 2.219.087
EIC Pathfinder

NATURAL INTRAOCULAR PHOTOACTIVATION OF COMPOUNDS TO FIGHT RETINOPATHIES

This project aims to revolutionize retinopathy treatment by developing orally bioavailable drugs that target retinal tissue, reducing side effects and improving access to care.

€ 2.988.434
EIC Pathfinder

MULTIMODE NONLINEAR FIBER BASED ENDOSCOPIC IMAGING AND TREATMENT

MULTISCOPE aims to revolutionize optical diagnostics and therapy by developing a dual-function endoscopic device for real-time optical biopsy and cold atmospheric plasma treatment in gastrointestinal care.

€ 2.863.733